GlassScriptPhysician profile
Megan Drumm
NPI 1841835261
$4,204.80
in general payments reported to CMS, 2019-2025
24 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $545 · 2022: $1,088 · 2023: $1,400 · 2024: $710 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $625.23 | 2022-2025 | Barostim Neo System |
| Atricure, INC. | $463.99 | 2021-2025 | Atriclip Laa Exclusion System, Epi-Ease Epicardial Access System, Epi-Sense Guided Coagulation System With Visitrax |
| Impulse Dynamics (USA) INC. | $416.35 | 2022-2025 | Optimizer, Optimizer |
| Amgen INC. | $407.78 | 2021-2025 | Repatha, Repatha |
| Medtronic, INC. | $386.50 | 2022-2025 | Corevalve Evolut R, Venaseal |
| Novartis Pharmaceuticals Corporation | $356.75 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $343.52 | 2021-2023 | Xarelto |
| Pfizer INC. | $182.06 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $178.82 | 2023 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.82 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $120.01 | 2021-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $106.94 | 2021-2023 | Verquvo |
| Boston Scientific Corporation | $77.56 | 2022-2023 | Ekosonic |
| Abbott Laboratories | $76.32 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $69.59 | 2023 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $43.97 | 2024 | Arcalyst |
| Abiomed | $39.11 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.88 | 2022-2024 | Lifevest |
| Teleflex LLC | $20.96 | 2023 | Manta |
| Lexicon Pharmaceuticals, INC. | $19.48 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $18.92 | 2024 | Zio Monitor, Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $18.62 | 2023 | Farxiga |
| Convatec INC. | $15.97 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Drumm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.